- Home
- ACT vs ALKS Comparison
ACT vs ALKS Comparison
Compare ACT & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACT
- ALKS
- Stock Information
- Founded
- ACT 1981
- ALKS 1987
- Country
- ACT United States
- ALKS Ireland
- Employees
- ACT N/A
- ALKS N/A
- Industry
- ACT Specialty Insurers
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- ACT Finance
- ALKS Health Care
- Exchange
- ACT Nasdaq
- ALKS Nasdaq
- Market Cap
- ACT 5.1B
- ALKS 5.1B
- IPO Year
- ACT 2021
- ALKS 1991
- Fundamental
- Price
- ACT $37.80
- ALKS $28.75
- Analyst Decision
- ACT Buy
- ALKS Buy
- Analyst Count
- ACT 4
- ALKS 12
- Target Price
- ACT $37.75
- ALKS $40.00
- AVG Volume (30 Days)
- ACT 513.6K
- ALKS 1.8M
- Earning Date
- ACT 07-30-2025
- ALKS 07-23-2025
- Dividend Yield
- ACT 2.22%
- ALKS N/A
- EPS Growth
- ACT 9.98
- ALKS N/A
- EPS
- ACT 4.44
- ALKS 2.09
- Revenue
- ACT $1,216,974,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- ACT $4.51
- ALKS N/A
- Revenue Next Year
- ACT $4.46
- ALKS $4.25
- P/E Ratio
- ACT $8.51
- ALKS $13.69
- Revenue Growth
- ACT 4.52
- ALKS N/A
- 52 Week Low
- ACT $29.99
- ALKS $22.90
- 52 Week High
- ACT $37.97
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- ACT 65.06
- ALKS 38.57
- Support Level
- ACT $34.77
- ALKS $28.49
- Resistance Level
- ACT $37.95
- ALKS $30.00
- Average True Range (ATR)
- ACT 0.71
- ALKS 0.75
- MACD
- ACT 0.18
- ALKS -0.09
- Stochastic Oscillator
- ACT 94.69
- ALKS 10.80
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.